| 14th Jul 2025 7:00 am |
RNS |
Baxdrostat met primary endpt in BaxHTN PhIII trial |
| 4th Jul 2025 7:00 am |
RNS |
Imfinzi approved in the EU for bladder cancer |
| 1st Jul 2025 3:00 pm |
RNS |
Total Voting Rights |
| 24th Jun 2025 7:00 am |
RNS |
Datroway approved in US for EGFRm lung cancer |
| 17th Jun 2025 11:45 am |
RNS |
Holding(s) in Company |
| 13th Jun 2025 9:30 am |
RNS |
AstraZeneca enters into collaboration with CSPC |
| 12th Jun 2025 3:00 pm |
RNS |
Director/PDMR Shareholding |
| 6th Jun 2025 7:00 am |
RNS |
Fixed-duration Calquence approved in EU for 1L CLL |
| 2nd Jun 2025 3:05 pm |
RNS |
Block listing Interim Review |
| 2nd Jun 2025 3:00 pm |
RNS |
Total Voting Rights |
| 27th May 2025 7:00 am |
RNS |
Imfinzi recommended in EU for bladder cancer |
| 23rd May 2025 10:00 am |
RNS |
Director/PDMR Shareholding |
| 21st May 2025 1:45 pm |
RNS |
Director Declaration |
| 20th May 2025 7:00 am |
RNS |
Acquisition of EsoBiotec completed |
| 9th May 2025 7:00 am |
RNS |
Imfinzi improved DFS in early bladder cancer |
| 7th May 2025 7:30 am |
RNS |
Enhertu improved pCR in early-stage breast cancer |
| 6th May 2025 7:00 am |
RNS |
Calquence combination approved in EU for 1L MCL |
| 2nd May 2025 7:00 am |
RNS |
Breztri met primary endpoints in Ph3 asthma trials |
| 1st May 2025 4:00 pm |
RNS |
Director/PDMR Shareholding |
| 1st May 2025 3:00 pm |
RNS |
Total Voting Rights |
| 29th Apr 2025 7:10 am |
RNS |
Fixed-duration Calquence recommended in EU for CLL |
| 29th Apr 2025 7:05 am |
RNS |
Update on CAPItello-280 Phase III trial |
| 29th Apr 2025 7:00 am |
RNS |
1st Quarter Results |
| 22nd Apr 2025 7:00 am |
RNS |
Enhertu combination improved PFS in 1L HER2+ mBC |
| 11th Apr 2025 5:30 pm |
RNS |
Result of AGM |
| 4th Apr 2025 7:05 am |
RNS |
Imfinzi approved in EU for AEGEAN |
| 4th Apr 2025 7:00 am |
RNS |
Enhertu approved in EU in post-ET breast cancer |
| 1st Apr 2025 3:00 pm |
RNS |
Total Voting Rights |
| 31st Mar 2025 7:05 am |
RNS |
Calquence recommended for EU approval in 1L MCL |
| 31st Mar 2025 7:00 am |
RNS |
Imfinzi approved in the US for bladder cancer |
| 21st Mar 2025 10:58 am |
RNS |
AZN invests $2.5bn in Beijing R&D & manufacturing |
| 17th Mar 2025 7:10 am |
RNS |
Eneboparatide Phase III trial met primary endpoint |
| 17th Mar 2025 7:05 am |
RNS |
Imfinzi approved in EU for limited-stage SCLC |
| 17th Mar 2025 7:00 am |
RNS |
AstraZeneca to acquire EsoBiotec |
| 12th Mar 2025 6:00 pm |
RNS |
Holding(s) in Company |
| 7th Mar 2025 3:00 pm |
RNS |
Director/PDMR Shareholding |
| 7th Mar 2025 11:00 am |
RNS |
Notice of AGM |
| 7th Mar 2025 7:00 am |
RNS |
Imfinzi improved EFS in early-stage gastric cancer |
| 6th Mar 2025 3:00 pm |
RNS |
Director/PDMR Shareholding |
| 5th Mar 2025 3:00 pm |
RNS |
Director/PDMR Shareholding |
